Welcome to our dedicated page for Compugen news (Ticker: CGEN), a resource for investors and traders seeking the latest updates and insights on Compugen stock.
Compugen Ltd. (NASDAQ: CGEN) is a clinical-stage biopharmaceutical pioneer leveraging computational discovery to advance novel cancer immunotherapies. This news hub provides investors and researchers with timely updates on clinical trials, strategic partnerships, and therapeutic innovations emerging from Compugen's AI-driven platform.
Access authoritative updates on key developments including COM701 (anti-PVRIG), COM902 (anti-TIGIT), and collaborative programs with industry leaders. Our curated news collection simplifies tracking of pipeline progress, peer-reviewed research publications, and milestone achievements in immuno-oncology.
Content spans clinical trial results, regulatory milestones, and partner collaboration updates, offering a comprehensive view of Compugen's position in next-generation cancer treatment development. Bookmark this page for streamlined access to verified information about therapeutic candidates and computational discovery breakthroughs.
Compugen Ltd. (NASDAQ: CGEN) reported its Q3 2020 financial results, revealing a net loss of $7.8 million, or $0.09 per share, an increase from $6.5 million, or $0.10 per share, in Q3 2019. R&D expenses rose to $5.5 million from $4.3 million due to ongoing clinical studies. A noteworthy milestone was the initiation of a Phase 1/2 study for the anti-PVRIG antibody, COM701, in combination with Bristol Myers Squibb's Opdivo® and an investigational TIGIT antibody. Compugen's cash reserves reached approximately $133 million, significantly up from $44 million at year-end 2019.
Compugen Ltd. (CGEN) has received a new patent from the China National Intellectual Property Administration for COM902, an immuno-oncology therapeutic antibody targeting TIGIT. This patent extends the protection for COM902 beyond existing patents in the U.S. and Europe and covers its composition for cancer treatment. The patent is valid until at least August 2037. COM902 is currently in a Phase 1 clinical trial, showing potential to enhance T cell responses against tumors when combined with PD-1 inhibitors. This development reflects Compugen's commitment to expanding its immuno-oncology pipeline.
Compugen Ltd. (Nasdaq: CGEN) announced new research data on October 27, 2020, suggesting that PVRIG may enhance T cell priming and infiltration into tumors, potentially improving cancer immunotherapy outcomes. Presented at the 2020 TIGIT Therapies Digital Summit, findings indicate that PVRIG inhibition could benefit patients with unresponsive tumors. The data highlight PVRIG's role in T cell activation and its expression alongside TIGIT and PD-1, indicating that targeting this pathway could provide new treatment options.
Compugen Ltd. (Nasdaq: CGEN) announced it will release its third quarter 2020 financial results on November 5, 2020, before U.S. markets open. A conference call will take place at 8:30 AM ET to review the results and provide corporate updates. Compugen is a leader in cancer immunotherapy, with products like the first-in-class anti-PVRIG antibody COM701 under Phase 1 study, along with COM902 targeting TIGIT. The company focuses on predictive target discovery for therapeutics in immuno-oncology.
Compugen Ltd. (Nasdaq: CGEN) has announced the appointment of Dr. Nils Lonberg to its Scientific Advisory Board. Dr. Lonberg, a leader in immuno-oncology with over 30 years of experience, will replace Dr. Charles Drake, who is leaving to pursue a new role in the pharmaceutical industry. Compugen's CEO, Anat Cohen-Dayag, highlighted Dr. Lonberg's contributions to cancer treatment and his potential to enhance the company's efforts in immunotherapy. The company currently has ongoing clinical studies for its lead product candidate, COM701, an anti-PVRIG antibody.
Compugen Ltd. (CGEN) has initiated its Phase 1/2 study, dosing the first patient for a triple combination therapy using COM701, Opdivo®, and BMS-986207. This clinical trial aims to assess the safety and efficacy of targeting PVRIG and TIGIT alongside PD-1 pathways to enhance anti-tumor responses in patients with advanced solid tumors. The study will enroll approximately 100 patients and includes a biomarker-driven approach focusing on ovarian and endometrial cancers. Compugen's CEO expressed optimism about the partnership with Bristol Myers Squibb and the potential to improve immunotherapy options.
Compugen Ltd. (NASDAQ: CGEN) announced its participation in two upcoming virtual investor conferences. The first event is the Morgan Stanley Virtual 18th Annual Global Healthcare Conference on September 16, 2020, at 9:30 AM ET. The second event is the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 22, 2020, at 9:10 AM ET. Live webcasts of both presentations will be available on the Compugen website, with replays accessible afterward.
Compugen is focused on developing therapeutics in cancer immunotherapy, with lead candidates undergoing clinical trials.
Compugen Ltd. (NASDAQ: CGEN) announced the granting of a new patent by the USPTO for its immuno-oncology therapeutic antibody COM902, which targets TIGIT. The patent, U.S. Patent No. 10,751,415, secures the composition of matter for COM902, expiring no earlier than August 2037. This patent complements a previously issued patent covering its method of use in activating T cells, expanding intellectual property protection in the U.S. and Europe. COM902, currently in a Phase 1 trial, aims to enhance T cell function for patients with advanced malignancies.
Compugen Ltd. (Nasdaq: CGEN) reported its Q2 2020 financial results, highlighting advancements in cancer immunotherapy research. The company has initiated the Phase 1 monotherapy study of COM701 and is set to begin a triple combination study with its drugs, Opdivo®, and a TIGIT inhibitor by the end of 2020. Key findings include a 69% disease control rate in monotherapy and a 75% rate in combination therapy. Despite a net loss of $6.2 million, Compugen holds $136 million in cash, marking a significant increase from $44 million at the end of 2019.
Compugen Ltd. (Nasdaq: CGEN) will announce its second quarter 2020 financial results on July 30, 2020, prior to the U.S. market opening. Following the announcement, management will conduct a conference call at 8:30 AM ET to discuss the results and provide a corporate update. Investors can join the call via telephone or through a live webcast on Compugen's website. The company focuses on cancer immunotherapy, with lead candidates COM701 and COM902 currently in Phase 1 clinical studies.
FAQ
What is the current stock price of Compugen (CGEN)?
What is the market cap of Compugen (CGEN)?
